Related Experiment Video

Updated: Aug 10, 2026

Investigations on the Ga(III) Complex of EOB-DTPA and Its 68Ga Radiolabeled Analogue
11:22

Investigations on the Ga(III) Complex of EOB-DTPA and Its 68Ga Radiolabeled Analogue

Published on: August 17, 2016

Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update

C J Smith1, W A Volkert, T J Hoffman

  • 1Radiopharmaceutical Sciences Institute, University of Missouri, Columbia, MO 65211, USA.

Nuclear Medicine and Biology
|December 31, 2003
PubMed

Insights

Radiolabeled peptides targeting the gastrin releasing peptide (GRP) receptor show promise for cancer diagnosis and therapy. Research focuses on developing new GRP receptor-specific radiopharmaceuticals using various radiometal chelation systems.

Area of Science:

  • Oncology
  • Radiochemistry
  • Molecular Imaging

Background:

  • The gastrin releasing peptide (GRP) receptor is functionally expressed in neuroendocrine tumors, including prostate, breast, and small cell lung cancer.
  • This expression makes the GRP receptor an attractive target for developing novel diagnostic and therapeutic agents.

Purpose of the Study:

  • To review current efforts in developing new GRP receptor-specific radiopharmaceuticals.
  • To highlight the application of various radiometal chelation systems in this development.

Main Methods:

  • Review of existing research on GRP receptor-targeting radiopharmaceuticals.
  • Analysis of different radiometal chelation strategies employed.

Main Results:

  • Several approaches are being explored to create GRP receptor-specific radiolabeled peptides.
  • Various radiometal chelation systems are utilized to achieve diagnostic and therapeutic potential.

Conclusions:

  • The GRP receptor is a promising target for developing targeted cancer therapies and diagnostics.
  • Advancements in radiometal chelation systems are crucial for creating effective GRP receptor-based radiopharmaceuticals.

More Related Videos

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Published on: January 7, 2019

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Related Concept Videos

G-protein Coupled Receptors01:21

G-protein Coupled Receptors

G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...